Der Tagesspiegel widmete dem innovativen Simulationsmodell von Krebszellen aus dem Hause Alacris – ModCell – einen ausführlichen Artikel: Alacris untersucht Tumorzellen mithilfe der Next-Generation Sequenzierung auf ihre genetische Zusammensetzung. Im Computermodell ModCell werden diese Informationen als digitale Zwillinge der Zellen nachgebaut und mögliche Medikationen simuliert. Künftig könnten Onkologen dank ModCell in Frage kommende Therapien vorab […]
Alacris Theranostics startet Seedmatch-Crowdfunding-Kampagne für einzigartige computergestützte Tumoranalyse zur Optimierung von KrebstherapienJeder Mensch ist anders und Tumore besonders – ein Grund warum viele Krebstherapien heute immer noch scheitern. Damit der Krebs erfolgreich bekämpft werden kann, muss eine Therapie die Schwachstellen ihres Gegners erkennen können, also den individuellen Eigenheiten des Tumors angepasst werden. Alacris‘ Comprehensive Molecular […]
Alacris Theranostics was honored for the second time in a row by the “Stifterverband für die Deutsche Wissenschaft” for its research competence and innovative ability. The Stifterverband has set itself the task of investigating and evaluating the German research and innovation system. Accordingly the association carries out an annual R & D survey on behalf […]
European Commission supports DigiTwins On Friday, 18th of May, DigiTwins received an invitation from the European Commission to enter the nextstage of the competition to become an EU Flagship for Future and Emerging Technologies. DigiTwins, alarge research initiative in Europe and beyond aims at revolutionizing healthcare and biomedical researchfor the benefit of citizens and society […]
New biomarkers for bowel cancer treatment Scientists can predict in the lab whether a drug will be effective for individual colorectal tumors Colorectal carcinomas arise in different forms, so all treatments do not work for all patients. OncoTrack, a public-private consortium supported by the Innovative Medicines Initiative Joint Undertaking, has conducted one of Europe’s largest […]
The quality management of Alacris Theranostics GmbH has been certified by TÜV Süd according to ISO 9001:2015. Alacris therefore fulfills the requirements for a quality management system according to the latest revision of ISO 9001. Alacris focuses on personalized medicine and requires its own state-of-the-art next-generation sequencing lab with an efficient sequencing and data analysis […]
Der Stifterverband für die Deutsche Wissenschaft e.V has honored Alacris’ innovations with his seal of approval. Since 2014 the Stifterverband honors research companies for the particular responsibility they assume for state and society, with this seal of approval, and after answering a detailed questionnaire submitted by the Stifterverband, it is official: Alacris is “Innovative through […]
An international group of scientists from 6 countries bring together their expertise to develop a combined experimental and systems biology platform for predictive modelling of cancer signalling. The EU Horizon 2020 funded project, co-ordinated by Alacris Theranostics GmbH, Berlin, will run for 5 years with a budget of almost 11 million euros. The European Research […]
The 2016 Biotechnology Awards showcase the very best talent, dedication and discoveries from firms working in the field of healthcare.Alacris’ revolutionary systems medicine modelling approach (ModCell™), to better match patients to therapies (‘virtual patients’) and therapies to patients (‘virtual clinical trials’) and Alacris’ unique oncogenomic pipeline was selected by the jury for “Best for Cancer […]
Alacris Theranostics GmbH was announced today, February 24th 2016, winner of the Gold Stevie® Awards as well in the categorie “Innovativstes Unternehmen des Jahres – Bis zu 100 Mitarbeiter” (Most innovative enterprise – up to 100 employees) as in the category “Unternehmen des Jahres – Gesundheitsprodukte & Dienstleistungen” (Enterprise of the Year – Health solutions) […]